India Targeted Cancer Therapies Market Size & Growth Rate
According to 6Wresearch internal database and industry insights, the India Targeted Cancer Therapies Market was valued at USD 508.0 million in 2025 and is projected to reach USD 784.25 million by 2032, growing at a CAGR of approximately 6.4% during 2026–2032.
India Targeted Cancer Therapies Market Highlights
| Report Metric | Details |
| Report Name | India Targeted Cancer Therapies Market |
| Market Size 2025 | USD 508.0 million |
| Market Size 2032 | USD 784.25 million |
| Absolute Growth 2025–2032 | USD 276.25 million |
| CAGR 2026–2032 | 6.4% |
| Peak Annual Growth | 8.8% in 2028 |
| Forecast Period | 2026–2032 |
| Historical Data | 2022–2025 |
| Base Year | 2025 |
| Leading Therapy Type, 2025 | Monoclonal Antibodies (52% share) |
| Leading Target Biomarker, 2025 | HER2/EGFR (51% share) |
| Leading Administration Route, 2025 | Intravenous (53% share) |
| Leading End User, 2025 | Oncology Clinics (51% share) |
| Fastest-Growing Therapy Type | Tyrosine Kinase Inhibitors (8.9% CAGR) |
| Fastest-Growing Target Biomarker | BCR-ABL/VEGFR (8.1% CAGR) |
| Fastest-Growing Administration Route | Oral (7.8% CAGR) |
| Fastest-Growing End User | Hospitals (8.9% CAGR) |
| Growing Sector | Oncology Clinics |
| Key End Users | Oncology Clinics, Hospitals, Cancer Research Centers |
India Targeted Cancer Therapies Market Year-wise Growth Rate and Key Drivers (2022–2032)
This graph illustrates the annual growth rates of the market from 2022 to 2032, highlighting a steady upward trajectory and projected market expansion over the forecast period.
The table below sets out the estimated growth rate for each year and the main factor behind it.
| Year | Estimated Annual Growth (%) | Market Rationale |
| 2022 | 6.2 | The market showed steady demand for targeted therapies among healthcare providers and research institutions. |
| 2023 | 7.8 | Increased awareness and the National Cancer Registry Programme contributed to faster growth this year. |
| 2024 | 4.2 | Growth slowed as healthcare providers adjusted to new treatment protocols and guidelines. |
| 2025 | 3.6 | Demand continued to slow as the market stabilised after previous rapid growth phases. |
| 2026 | 5.6 | A resurgence in investment in cancer research and treatment facilities is expected to boost growth. |
| 2027 | 6.7 | Healthcare providers are likely to increase adoption of targeted therapies, driving demand further. |
| 2028 | 8.8 | The introduction of new targeted therapies is anticipated to peak market growth this year. |
| 2029 | 8.4 | Market growth is expected to slow slightly as competition among therapies intensifies. |
| 2030 | 4.9 | Demand will continue to grow, albeit at a slower rate as treatment protocols evolve. |
| 2031 | 4.5 | The market is projected to experience another slowdown as treatment options become more standardised. |
| 2032 | 6.0 | Growth is expected to pick up again as new therapies gain traction among healthcare providers. |
Note: Market size estimations and growth projections presented in this report are based on 6Wresearch's proprietary forecasting methodology, utilizing the latest available industry data, government publications, and primary research inputs.
India Targeted Cancer Therapies Market Synopsis
Targeted Cancer Therapies in India are advanced treatments designed to specifically target cancer cells based on genetic characteristics. These therapies include monoclonal antibodies and tyrosine kinase inhibitors, aimed at improving patient outcomes while minimising side effects. The India Targeted Cancer Therapies Market is expanding due to the increasing number of cancer cases, with over 1 million reported annually. Demand is primarily driven by oncology clinics and hospitals, supported by the National Cancer Control Programme's goal to reduce cancer mortality by 30% by 2025.
Market Dynamics Impact Analysis (2026–2032)
| Factor | Type | Impact | Primary Segment Affected |
| Rising cancer incidence drives demand for effective treatment options. | Driver | High | Monoclonal Antibodies |
| Investment in oncology clinics expands treatment capacity and access. | Driver | High | Oncology Clinics |
| Growing need for innovative therapies presents opportunities for suppliers. | Opportunity | High | Tyrosine Kinase Inhibitors |
| Increased focus on personalised medicine opens new markets for targeted therapies. | Opportunity | High | Hormonal Therapies |
| High costs of targeted therapies can limit accessibility for patients. | Restraint | High | Immunotherapies |
| Regulatory hurdles can delay the introduction of new therapies. | Restraint | Medium | Monoclonal Antibodies |
| Limited awareness among patients affects treatment uptake. | Challenge | High | Oncology Clinics |
| Competition among various treatment options can confuse buyers. | Challenge | Medium | Hospitals |
Evaluation of Drivers in India Targeted Cancer Therapies Market (2026–2032)
The main growth drivers and the segments they affect most are set out below.
| Drivers | Primary Segment Affected | Why It Matters (Evidence) |
| Increased cancer awareness leads to higher patient consultations. | Monoclonal Antibodies | With over 1 million new cases annually, oncology clinics see more patients seeking targeted therapies. |
| Expansion of oncology clinics improves patient access to treatments. | Oncology Clinics | The presence of over 200 clinics across major cities facilitates better treatment availability. |
| Investment in cancer research promotes therapy development. | Tyrosine Kinase Inhibitors | The Indian Council of Medical Research supports initiatives that advance cancer therapies. |
| Rising healthcare expenditure boosts spending on advanced treatments. | Immunotherapies | Healthcare spending in India is projected to reach USD 370 billion by 2025, increasing therapy purchases. |
| Collaboration with international research institutions accelerates therapy advancements. | Hormonal Therapies | International partnerships improve local capabilities, leading to more effective treatment options. |
Market growth in India for Targeted Cancer Therapies rests on rising cancer incidence, increasing healthcare expenditure, and expanding treatment facilities. The country reports over 1 million new cancer cases annually, prompting healthcare providers to seek effective therapies. Investment in oncology clinics has reached USD 370 billion, improving access to treatments. Collaborations with international research institutions are driving innovation in therapy development, particularly in immunotherapies. As a result, the average patient population receiving targeted therapies is around 300,000, creating a growing demand for advanced treatment options.
Evaluation of Restraints in India Targeted Cancer Therapies Market
The key brakes on demand, and where they bite hardest, are shown below.
| Market Restraint | Primary Segment Affected | Why It Matters (Evidence) |
| High costs limit patient access to targeted therapies. | Immunotherapies | The average cost of advanced therapies can exceed USD 30,000, making them unaffordable for many patients. |
| Regulatory delays can hinder therapy approvals. | Monoclonal Antibodies | The Drug Controller General of India oversees approvals, which can take several months, delaying market entry. |
| Limited patient awareness affects treatment choices. | Oncology Clinics | Many patients are unaware of the benefits of targeted therapies, resulting in lower adoption rates. |
| Competition among therapies can confuse healthcare providers. | Hospitals | With numerous treatment options available, providers may struggle to choose the most effective therapies. |
| Inconsistent treatment protocols can lead to variable outcomes. | Hormonal Therapies | The Oncology Society of India provides guidelines, but adherence varies among practitioners. |
India Targeted Cancer Therapies Market Challenges
Buyers in the India Targeted Cancer Therapies market face escalating treatment costs, with average annual expenses reaching ₹3 lakh per patient, making access to care challenging for many individuals. Regulatory hurdles persist as the Drug Controller General of India often takes six months to approve new therapies, delaying timely access for patients needing advanced treatments. A shortage of skilled oncology professionals limits the distribution of targeted therapies, affecting around 300,000 patients who could otherwise benefit from these innovations. Intense competition exists among over 200 oncology clinics, which pressures pricing and can compromise service quality for patients seeking care.
Trends in the India Targeted Cancer Therapies Market
The trends below show where the India Targeted Cancer Therapies Market is heading.
- Shift towards Personalised Medicine: India is increasingly adopting personalised medicine approaches in cancer treatment, focusing on genetic profiling. The National Cancer Control Programme aims to reduce mortality by 30% by 2025, promoting tailored therapies. This shift improves treatment efficacy and patient outcomes.
- Growth of Immunotherapy Approaches: The use of immunotherapies is expanding in India, with a growing number of clinical trials underway. The average patient population receiving these therapies is around 300,000, reflecting increased interest and investment in this treatment type.
- Expansion of Oncology Clinics: More oncology clinics are being established across major cities, improving access to targeted therapies. With over 200 clinics operating, patient consultations are expected to rise, enhancing treatment uptake and outcomes.
- Increased Collaboration in Cancer Research: Collaboration between Indian and international research institutions is fostering innovation in cancer therapies. The Indian Council of Medical Research is actively funding projects that develop new treatment options, driving market growth.
Investment Opportunities in the India Targeted Cancer Therapies Market
Several openings in the India Targeted Cancer Therapies Market merit attention from investors.
- Investment in Oncology Clinics: With over 200 oncology clinics in India, there is a strong opportunity to invest in expanding these facilities. The National Health Mission promotes cancer awareness, which can drive patient volume and treatment adoption.
- Focus on Innovative Therapies: The growing demand for innovative therapies presents a unique investment opportunity. The average population of cancer patients receiving targeted therapies is around 300,000, indicating a strong market for new treatment options.
- Development of Oral Administration Therapies: The shift towards oral administration of therapies is gaining traction, appealing to a broader patient base. This trend is particularly relevant for outpatient treatment, enhancing convenience for patients.
- Support for Research Initiatives: Investing in cancer research initiatives is timely, given the government's focus on reducing cancer mortality. The National Institute of Cancer Prevention and Research conducts studies on treatment efficacy, creating opportunities for new therapies.
Government Initiatives in the India Targeted Cancer Therapies Market
The New Drug Approval Process, implemented by the Drug Controller General of India in 2021, streamlines the approval of new cancer therapies. This measure improves the efficiency of bringing new treatments to market, benefiting both producers and patients by reducing waiting times for new therapies. The National Cancer Control Programme aims to reduce cancer mortality by 30% by 2025, enhancing overall treatment access.
The Indian Council of Medical Research plays a vital role in funding cancer research initiatives. It supports various projects aimed at improving treatment efficacy and patient outcomes, ensuring that advancements in targeted therapies are effectively translated into clinical practice. The agency also collaborates with hospitals and clinics to facilitate the implementation of new therapies.
Future Insight of the India Targeted Cancer Therapies Market
Several forward-looking factors should support the India Targeted Cancer Therapies market by 2032. The National Health Mission's cancer awareness programs are expected to drive increased patient engagement and demand for targeted treatments. Enhanced research initiatives from the Indian Council of Medical Research will lead to breakthroughs in drug development, expanding treatment options. The anticipated growth of over 300 oncology clinics across major cities will improve patient access to therapies, creating a more competitive landscape for suppliers.
Market Segmentation Analysis
Each segment group is reviewed below, with the leader by share and the fastest grower by CAGR.
By Therapy Type – Monoclonal Antibodies Dominated, Tyrosine Kinase Inhibitors Expected to Grow Fastest
According to Sumit Sagar, AM at 6Wresearch, Monoclonal Antibodies held a 52% share of the India Targeted Cancer Therapies Market by therapy type in 2025. Monoclonal antibodies command a substantial share of the India Targeted Cancer Therapies Market due to their extensive use in specific cancer treatments since 2015. This therapy type benefits from a strong installed base, with a significant number of patients experiencing positive outcomes from targeted approaches. Over 2026–2032, Tyrosine Kinase Inhibitors are expected to post the fastest growth, at a CAGR of 8.9%. Tyrosine kinase inhibitors are rapidly gaining popularity, as their effectiveness in targeted therapies for various cancers becomes increasingly acknowledged. Their growth is propelled by ongoing clinical trials and research that highlight their potential to improve patient outcomes significantly. This trend indicates that suppliers should focus on enhancing their monoclonal antibody offerings while also investing in the development of tyrosine kinase inhibitors to cater to the growing demand.
By Target Biomarker – HER2/EGFR Dominated, BCR-ABL/VEGFR Expected to Grow Fastest
HER2/EGFR accounted for a 51% market share by target biomarker in 2025. HER2/EGFR biomarkers hold a leading position in market share due to their critical role in the effectiveness of targeted therapies for specific cancer types. Their established presence in treatment protocols makes them a preferred choice among healthcare providers across India. BCR-ABL/VEGFR is set to record the highest CAGR in this split, 8.1% over 2026–2032. BCR-ABL/VEGFR biomarkers are witnessing the fastest growth, driven by their essential role in treating particular cancer types, which is gaining recognition through increased research and clinical applications. This aligns with the broader trend towards personalised medicine in oncology, enhancing their relevance. For suppliers, this suggests a strategic focus on developing therapies targeting BCR-ABL/VEGFR could create new market opportunities.
By Administration Route – Intravenous Dominated, Oral Expected to Grow Fastest
In 2025, Intravenous led the administration route split with a 53% share. Intravenous administration is the predominant route for targeted cancer therapies, being the most common method employed in oncology clinics throughout India. This route allows for effective delivery of treatments directly into the bloodstream, ensuring prompt therapeutic action. The quickest growth will come from Oral, forecast to expand at a CAGR of 7.8% between 2026 and 2032. Oral administration is experiencing rapid growth due to its convenience for outpatient treatment, allowing patients to manage their therapy more easily at home. This trend is supported by advancements in formulation technologies that enhance drug absorption and patient compliance. Suppliers should consider expanding their product lines to include more oral administration options to align with patient preferences and improve adherence.
By End User – Oncology Clinics Dominated, Hospitals Expected to Grow Fastest
Oncology Clinics took a 51% share of end user in 2025, more than any other category. Oncology clinics are the primary users of targeted therapies, capturing the largest market share due to their specialisation in comprehensive cancer care. Their focused approach enables tailored treatment plans that significantly improve patient outcomes and satisfaction. Hospitals are projected to grow fastest, at a CAGR of 8.9% during 2026–2032. Hospitals are experiencing the fastest growth as major treatment centres for cancer, driven by increasing patient volumes and the rising demand for advanced therapeutic options. This trend reflects a shift towards integrated cancer care within hospital environments, enhancing their importance. Suppliers should strengthen partnerships with hospitals to ensure their products are integrated into treatment protocols, capitalising on this expanding user base.
Key Attractiveness of the Report
- 10 Years of Market Numbers
- Historical Data Starting from 2022 to 2025
- Base Year 2025
- Forecast Data until 2032
- Key Performance Indicators Impacting the Market
- Major Upcoming Developments and Projects
Key Highlights of the Report:
- India Targeted Cancer Therapies Market Outlook
- Market Size of India Targeted Cancer Therapies Market, 2025
- Forecast of India Targeted Cancer Therapies Market, 2032
- Historical Data and Forecast of India Targeted Cancer Therapies Revenues & Volume for the Period 2022 - 2032F
- India Targeted Cancer Therapies Market Trend Evolution
- India Targeted Cancer Therapies Market Drivers and Challenges
- India Targeted Cancer Therapies Price Trends
- India Targeted Cancer Therapies Porter's Five Forces
- India Targeted Cancer Therapies Industry Life Cycle
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Therapy Type for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Monoclonal Antibodies for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Tyrosine Kinase Inhibitors for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Hormonal Therapies for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Immunotherapies for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Target Biomarker for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By HER2/EGFR for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By BCR-ABL/VEGFR for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Estrogen/Testosterone for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By PD-1/CTLA-4 for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Administration Route for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Intravenous for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Oral for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Oral/Injection for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By IV/Subcutaneous for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By End User for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Oncology Clinics for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Specialty Hospitals for the Period 2022 - 2032F
- Historical Data and Forecast of India Targeted Cancer Therapies Market Revenues & Volume By Cancer Research Centers for the Period 2022 - 2032F
- India Targeted Cancer Therapies Import Export Trade Statistics
- Market Opportunity Assessment By Therapy Type
- Market Opportunity Assessment By Target Biomarker
- Market Opportunity Assessment By Administration Route
- Market Opportunity Assessment By End User
- India Targeted Cancer Therapies Top Companies Market Share
- India Targeted Cancer Therapies Competitive Benchmarking By Technical and Operational Parameters
- India Targeted Cancer Therapies Company Profiles
- India Targeted Cancer Therapies Key Strategic Recommendations
Market Covered
Segments analysed in this report are listed below.
By Therapy Type
- Monoclonal Antibodies
- Tyrosine Kinase Inhibitors
- Hormonal Therapies
- Immunotherapies
By Target Biomarker
- HER2/EGFR
- BCR-ABL/VEGFR
- Estrogen/Testosterone
- PD-1/CTLA-4
By Administration Route
- Intravenous
- Oral
- Oral/Injection
- IV/Subcutaneous
By End User
- Oncology Clinics
- Hospitals
- Specialty Hospitals
- Cancer Research Centers
